Answers are grounded in this paper and cite their sources.
The incidence of acute renal failure, defined by the risk, injury, or failure criteria of the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease), in 66 patients who received colistimethate sodium was 45%, and 21% of patients stopped therapy because of nephrotoxicity. The RIFLE criteria should be used in the future to allow for comparison of nephrotoxicity among studies.
No takes yet. Share an insight, caveat, or question.
Hartzell et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: